Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
66.49
+1.09 (1.67%)
May 14, 2025, 9:44 AM - Market open
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
6.64
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
291.59B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
NVO News
- 2 hours ago - Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - WSJ
- 2 hours ago - Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters
- 1 day ago - NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs - FXEmpire
- 1 day ago - Novo Nordisk: A Strategy With High Potential For Volatile Times - Seeking Alpha
- 1 day ago - 50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy - Seeking Alpha
- 1 day ago - Trump calls out weight-loss drugs as target of price-cut push - Reuters
- 1 day ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 1 day ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha